BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29078133)

  • 1. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
    Basile D; Cinausero M; Iacono D; Pelizzari G; Bonotto M; Vitale MG; Gerratana L; Puglisi F
    Cancer Treat Rev; 2017 Dec; 61():15-22. PubMed ID: 29078133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
    Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
    Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
    Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
    Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
    Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
    J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of PDEF factor expression and its relation to androgen receptor in ER
    Cao L; Li C; Xu C; Xiang G; Liu F; Liu X; Jiao J; Lv S; Niu Y
    Histopathology; 2018 Nov; 73(5):819-831. PubMed ID: 29969155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
    Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
    Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the AR/ER ratio in ER-positive breast cancer patients.
    Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
    Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
    Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
    Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
    BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.
    Salvi S; Bonafè M; Bravaccini S
    Semin Cancer Biol; 2020 Feb; 60():132-137. PubMed ID: 31002873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal breast cancer, androgens, and aromatase inhibitors.
    Campagnoli C; Pasanisi P; Castellano I; Abbà C; Brucato T; Berrino F
    Breast Cancer Res Treat; 2013 May; 139(1):1-11. PubMed ID: 23572296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
    Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
    Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
    [No Abstract]   [Full Text] [Related]  

  • 15. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
    Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
    Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.
    Vera-Badillo FE; Templeton AJ; de Gouveia P; Diaz-Padilla I; Bedard PL; Al-Mubarak M; Seruga B; Tannock IF; Ocana A; Amir E
    J Natl Cancer Inst; 2014 Jan; 106(1):djt319. PubMed ID: 24273215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
    Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
    Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
    Nahleh Z
    Future Oncol; 2008 Feb; 4(1):15-21. PubMed ID: 18240997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is It Time to Consider the Androgen Receptor as a Therapeutic Target in Breast Cancer?
    Forooshani MK; Scarpitta R; Fanelli GN; Miccoli M; Naccarato AG; Scatena C
    Anticancer Agents Med Chem; 2022; 22(4):775-786. PubMed ID: 34852747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.